Genmab (GMAB) files Form 6-K on Q3 2025 DARZALEX net sales announcement

Rhea-AI Filing Summary

Genmab A/S submitted a Form 6-K as a foreign private issuer for October 2025. The filing makes a company announcement, dated October 14, 2025, available as an exhibit, which covers net sales of DARZALEX (daratumumab) for the third quarter of 2025.

The Form 6-K is also deemed incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the information in this report becomes part of those employee equity compensation-related disclosures.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF OCTOBER 2025

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated October 14, 2025: Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: OCTOBER 14, 2025

FAQ

What does Genmab A/S report in this Form 6-K for GMAB?

Genmab A/S files a Form 6-K providing a company announcement about net sales of DARZALEX (daratumumab) for the third quarter of 2025. The announcement is attached as Exhibit 99.1 and is dated October 14, 2025.

Which product’s performance is highlighted in Genmab (GMAB) October 2025 Form 6-K?

The Form 6-K highlights net sales information for DARZALEX (daratumumab). This cancer therapy’s third quarter 2025 net sales are discussed in the company announcement attached as Exhibit 99.1 to the filing, dated October 14, 2025.

How is this Genmab (GMAB) Form 6-K used in existing registration statements?

The report is deemed incorporated by reference into Genmab’s existing Form S-8 registration statements. This means the information in the Form 6-K becomes part of those employee share compensation-related filings from the date the report is filed.

Which Genmab Form S-8 registration statements reference this October 2025 Form 6-K?

The Form 6-K is incorporated by reference into Genmab’s Form S-8 registration statements with file numbers 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876. This linkage updates those registrations with the new information.

Who signed the October 2025 Genmab (GMAB) Form 6-K?

The Form 6-K was signed on behalf of Genmab A/S by Anthony Pagano. He is identified in the document as Executive Vice President and Chief Financial Officer and signed the report dated October 14, 2025.